Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has C. Zhou's publication output changed over time?
ScholarIQpublication output · 2013–2023
Output grew0% over the shown period — from 1 works in 2013 to 1 in 2023.
1
1
1
1
3
3
1
2013201520172018201920212023
What are the most-cited papers on C. Zhou?
ScholarIQmost cited works
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
C. Zhou, Yi‐Long Wu, G. Chen, J. Feng, Xuetong Liu, C. Wang, S. Zhang, J. Wang, Songwen Zhou, Shengxiang Ren, Shun Lü, L. Zhang, Chengping Hu, Chengping Hu, Yi Luo, Lin Chen, M. Ye, Juanjuan Huang, X. Zhi, Y. Zhang, Qingyu Xiu, W. F. Mader, L. Zhang, Changxuan You
Annals of Oncology. 2015468 Citations
Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
Suresh S. Ramalingam, Yi Cheng, C. Zhou, Y. Ohe, Fumio Imamura, Byoung Chul Cho, Meng‐Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, A. Todd, Aleksandra Markovets, J. Carl Barrett, Juliann Chmielecki, Jhanelle E. Gray
Annals of Oncology. 2018357 CitationsOPEN ACCESS
Metformin Reprograms Tryptophan Metabolism to Stimulate CD8+ T-cell Function in Colorectal Cancer
Xiaowen Huang, Tiantian Sun, Jilin Wang, Xialu Hong, Huimin Chen, Tingting Yan, C. Zhou, Danfeng Sun, Chen Yang, TaChung Yu, Wenyu Su, Wan Du, Hua Xiong
Cancer Research. 2023102 Citations
ROS1 fusions in Chinese patients with non-small-cell lung cancer
W. Cai, X. Li, Chunxia Su, Lihong Fan, Li-Mou Zheng, K. Fei, C. Zhou, C. Manegold, Gerald Schmid‐Bindert
Annals of Oncology. 201390 Citations
2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC
C. Zhou, Meghna Das Thakur, Manoj Srivastava, Wen Zou, Hongjie Xu, M. Ballinger, Enriqueta Felip, Heather A. Wakelee, Nasser K. Altorki, Martin Reck, Rüediger Liersch, Anna Kryzhanivska, M. Harada, Hiroshi Tanaka, John Hamm, Steve McCune, Virginia McNally, Elizabeth Bennett, Barbara J. Gitlitz, Silvia Novello
Annals of Oncology. 202176 Citations
Related on ScholarIQ
Shanghai Jiao Tong University
Institution
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
Paper
Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
Paper
Metformin Reprograms Tryptophan Metabolism to Stimulate CD8+ T-cell Function in Colorectal Cancer
Paper
ROS1 fusions in Chinese patients with non-small-cell lung cancer
Paper
2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC
Paper